COYA Treg-directed combo therapies show early promise in ALS, FTD
TradingView News reports COYA’s Treg-directed combination therapies show promising early clinical signals in ALS and FTD, with key data expected in 2027.
A focused neurodegeneration pipeline leverages Treg-directed combination therapies, with promising early clinical signals in ALS and FTD and a Nobel-recognized scientific foundation.
Strategic partnerships, robust financials, and strong IP position support advancement toward key milestones in 2026—…